Lung Cancer Archives
Three of 13 attributes identified had the highest potential for reduced spending without compromising care.
Patients with PD-L1-positive malignancies have shown higher response rates to immune checkpoint inhibition and consequently prolonged progression-free/overall survival compared with others.
Treatment with osimertinib is associated with longer progression-free survival in patients with previously untreated EGFR mutation-positive advanced non-small-cell lung cancer.
Between 2000 and 2010, researchers identified a decline in the number of patients with stage I NSCLC who remained untreated.
Results of two phase 3 studies found that nivolumab provided superior overall survival vs docetaxel in people with non-small cell lung cancer.
Trial results provided strong evidence against the use of anticoagulant low molecular weight heparin in SCLC.
Patients with lung cancer and atherosclerosis diagnosis may benefit from anti-inflammatory therapy with canakinumab.
Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.
Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.
PanCan study effectively identified patients who eventually developed early-stage lung cancer, compared to other predictive models.
The ACCP just released new lung cancer screening guidelines.
Researchers surveyed knowledge, beliefs, attitudes, barriers, and facilitators related to screening patients for lung cancer.
Pazopanib improves progression-free survival in patients with small-cell lung cancer.
First generation EGFR tyrosine kinase inhibitors should be used in combination with chemotherapy if a patient has progressive EGFR mutation-positive non-small cell lung cancer.
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
Tumor lysis syndrome can occur even in the absence of chemotherapy, and clinicians should remain suspicious when patients demonstrate laboratory abnormalities.
Overall and progression-free survival were improved with greater depth of response to therapy in non-small cell lung cancer.
Patients with metastatic lung cancer who receive both both immune checkpoint inhibitors and thoracic radiotherapy.do not have a greater risk for immune-related adverse events.
Adjuvant adoptive cellular immunotherapy plus chemotherapy improved survival in patients with resected non-small cell lung caner.
Thoroughness of nodal examination determines prognostic value of non-small cell lung cancer staging.
ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.
A new diagnostic test and algorithm may be able to diagnose lung cancer from tumor-educated platelets.
Smokers with HIV who are adherent to antiretroviral therapy are still likely to die from lung cancer.
Higher doses of chemoradiation in stage 3 non-small cell lung cancer did not improve overall survival rates.
There may be a decreased rate of lung cancer for patients who receive anti-inflammatory therapy with canakinumab.
Fewer than 30% of patients undergoing durvalumab therapy experienced either grade 3 or 4 adverse events.
Recommendations to include CT scans as standard follow-up procedure is based on poor evidence.
Bevacizumab-awwb was approved based on pharmacokinetic and pharmacodynaic profiles and immunogenicity, safety, and efficacy data.
Canakinumab vs placebo showed promising results in preventing recurrent cardiovascular events and incidences of lung cancer.
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.
A retrospective study of lung cancer clinical trials found that trials continue to increase their eligibility criteria, creating barriers to patient access.
Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.
Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.
Patients who underwent lung CT screening had a higher 2-week smoking cessation rate vs patients who did not undergo screening.
Recent research suggests that perioperative and postoperative pulmonary rehabilitation improves outcomes in patients undergoing thoracic surgery.
Patients who underwent alternative therapies were more likely to die vs those who underwent usual care.
Men and male smokers were most impacted by the association between vitamin B6 and B12 supplementation and lung cancer risk.
Physicians can differentiate between benign and malignant pulmonary nodules, but do not consistently follow guideline-based recommendations when selecting the next diagnostic test.
Palifosfamide added to carboplatin and etoposide did not prolong survival among patients with extensive-stage small-cell lung cancer.
Over 18,000 cases of incident lung cancer were identified over mean 9.4 years of follow-up.
ASCO has released updated guidelines to help physicians manage nausea and vomiting caused by antineoplastic agents in cancer patients.
Caregivers often rate patients as having poorer functional status than patients rate themselves.
Valuable information regarding patients' life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.
Childhood intelligence scores are associated with lower risk of mortality caused by coronary heart disease, cancers related to smoking, respiratory diseases, digestive diseases, injury, and dementia.
Researchers considered the response rate "encouraging" and comparable to cisplatin-based neoadjuvant therapy outcomes.
Patients with metastatic lung cancer require careful considerations concerning quality of life.
Intense exposure over the course of a single day has been linked to an elevated risk of developing chronic health conditions.
The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.
Does Maintenance Pembrolizumab Improve Progression-Free, Overall Survival in Small-cell Lung Cancer?
Pembrolizumab may improve survival among patients with ES-SCLC
Results showed that proton-beam therapy in small-cell lung cancer can be safe in combined modality therapy.
Findings in patients with previously untreated disease with PD-L1 expression level of 5%.
Increased radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with advanced NSCLC.
Electronic medical records inadequate for determining whether patients meet pack-year requirement for lung cancer screening researchers warn.
Adjuvant gefitnib increases disease-free survival for patients with stage II to III non-small lung cancer.
Data can be used to target the development of new drugs for treating squamous cell carcinomas.
ASTRO releases guidelines on stereotactic body radiation therapy for early-stage non-small cell lung cancer
Lung cancer diagnosis raised the odds of suicide by over four times in comparison to the general population according to a study presented at annual meeting of ATS.
The added combination of selumetinib with docetaxel did not improve progression-free survival among patients previously treated for advanced NSCLC.
Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.
Two new medications may improve survival for patients with specific types of advanced non-small-cell lung cancer.
A report published in the Journal of the National Cancer Institute suggests that the FDA should require cigarette filters to remove the holes.
Participants in the phase 3 PACIFIC trial randomly received sequential treatment with either durvalumab or placebo.
Alectinib, a selective ALK inhibitor, was found to have an objective response rate of 92% among patients with ALK-positive NSCLC.
Approval was based on tumor response rate and progression-free survival data, gathered from the KEYNOTE-021 study.
The Food and Drug Administration (FDA) has granted accelerated approval to Alunbrig (brigatinib; ARIAD) tablets.
FDA grants Pfizer's lorlatinib the Breakthrough Therapy designation for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Continuous thoracic paravertebral nerve block, epidural anesthesia similarly effective for the management of postthoracotomy pain.
Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage non-small cell lung cancer.
Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA test among patients with advanced non-small cell lung cancer.
Atezolizumab was approved for patients with non-small cell lung cancer.
Annual lung cancer screenings using low-dose computed tomography among high-risk individuals remain "low and unchanged."
Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced non-small cell lung cancer.
The FDA approved osimertinib for treatment of EGFR T790M mutation positive non-small cell lung cancer.
Definitive lung stereotactic body radiotherapy in elderly patients with inoperable lung cancer is safe and effective.
Research from the National Cancer Institute found persistent racial disparities in treatment and outcomes among patients with non-small cell lung cancer.